Latest news

Extended Collaboration with Crop Protection Company

30 October, 2020

Nanologica has signed an agreement for continued collaboration with the global agricultural company that Nanologica has been working with. The extended agreement includes the formulation of another new active ingredient for plant protection using Nanologica’s technology. The value of the agreement amounts to approximately MSEK 1,3. In September 2017, Nanologica entered into an agreement with a global agricultural company specialized in crop protection, with the purpose of improving the formulation of an active ingredient

Prof. Adam Feiler to Present at the Annual Surface and Materials Chemistry Symposium

19 October, 2020

The section for Surface and Materials Chemistry at the Swedish Chemical Society organizes The Annual Surface and Materials Chemistry Symposium, this year held on 21 – 22 October 2020. CTO of Nanologica, Prof. Adam Feiler, will during the symposium give a presentation on Development of porous silica particles for drug delivery. The symposium may be followed on Zoom after registration on https://asmcs.se/. Prof. Adam Feiler will present at 16.20 on Oct 21.

“En bättre värld är en bra affär” – artikel av Spotlight Stock Market

16 October, 2020

Stark tillväxt, tunga avtal i ryggen och en teknik med potential att förändra människors liv. Det är life science-företaget Nanologica. – “Vi har en produkt som kommer att slå världen med häpnad”, säger Andreas Bhagwani, vd på Nanologica. Läs hela artikeln här: https://spotlightstockmarket.com/sv/nanologica/

Nanologica utökar teknologiplattform

15 October, 2020

Nanologicas patentansökan med titeln ”Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia” har publicerats. Genom patentet söker Nanologica utöka sin teknologiplattform med användandet av tomma porösa partiklar för behandling av bland annat neurodegenerativa sjukdomar. Patentet avser skydda idén att använda tomma porösa partiklar för att adsorbera ämnen i lösning. En applikation av teknologin är att förebygga och/eller fördröja nedbrytning vid bland annat neurodegenerativa sjukdomar (NDD) och därigenom bromsa

CTO Adam Feiler comments on the granting of European patent protecting the manufacturing of porous silica particles for drug delivery

1 October, 2020

Nanologicas patent godkänt i Europa

30 September, 2020

European Patent Office har beviljat Nanologicas patent med titeln ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. Patentet skyddar bolagets teknologiplattform NLAB Spiro™ genom att ge ensamrätt på metoden för att tillverka partiklar som laddas med läkemedel för administrering genom bland annat inhalation. ”Det här patentet är en milstolpe för Nanologica och det är glädjande att vi nu har patentskydd i

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Categories

News archive